Ƙwayar magani ta farko da take taimakawa wajen rage lalacewar ƙwaƙwalwa ta samu yabo a matsayin mai muhimmanci.
Binciken ya kawo ƙarshen shekarun da aka shafe ba tare da nasara ba kuma ta ba da damar samun maganin cutar Alzheimer’s – nau’i mafi shahara na cutar mantuwa.
Sai dai ya zuwa yanzu tasirin maganin na lecanemab ba shi da yawa kuma ana ta tafka muhawara game da aikinsa a rayuwar mutane.
Ƙwayar na aiki ne tun a farko-farkon cutar, saboda haka wasu da dama maganin ba zai musu amfani ba idan ba a yi sa’ar gano ta da wuri ba. Lecanemab na kai wa sinadarin beta amyloid hari – wanda ke taruwa a ƙwaƙalwar masu fama da cutar mantuwa.
Ana kallon irin wannan ci gaban a matsayin nasara sakamakon yadda rashin nasara da sarewar gwiwa suka mamaye sashen binciken lafiya tsawon shekaru. Cibiyar Alzheimer’s Research UK ta bayyana sakamakon da “mai muhimmanci”.
Ɗaya daga cikin mutanen da suka ƙirƙiri shirin far wa amyloid shekara 30 da suka wuce shi ne Farfesa John Hardy. Ya ce abu ne na tarihi kuma yana da qwarin gwiwar
“mun fara ganin magani cutar mantuwa”.
Farfesa Tara Spires-Jones na Jami’ar Edinburgh ya ce sakamakon “babban abu ne saboda mun daɗe muna yin rashin nasara kwatakwata”.
A yanzu, masu cutar mantuwa na samun magungunan da ke taimaka musu rage matsalar, amma babu wadda ke sauya tsananin cutar.
Lecanemab garkuwa ce ta jiki – irin wadda jiki ke samu don ya fatattaki qwayoyin cuta – da ke ba da umarni ga sassan jiki su kori sinadarin amyloid daga ƙwaƙwalwa.
Amyloid sinadari ne da ke curewa waje ɗaya a tsakanin mavallan aika saƙo a ƙwaƙwalwa sannan su zama makarai da ke haifar da nau’in Alzheimer’s na cutar mantuwa.
An yi gwajin mai yawan gaske kan mutum 1,795 da ke matakin farko na cutar. An dinga ba su ƙwayar duk mako biyu.
Sakamakon da aka samu bayan gwajin farkon, an gabatar da shi ne a taron da aka yi a San Francisco, Amurka kuma aka wallafa shi a mujallar New England ta Likitanci. Sai dai ba magani da ke warkar da cutar nan take ba. Cutar ta cigaba da raba mutane da tunaninsu amma kaɗan – kamar ɗaya cikin huɗu a tsawon wata 18 da suka yi jinya.
Ana ci gaba da duba bayanan da aka samu a Amurka, inda nan gaba kaɗan za a tabbatar ko za a iya bai wa marasa ƙwayar lecanemab. Waɗanda suka ƙirƙiri maganin – Eisai and Biogen – sun tsara fara neman izinin amfani da ita a sauran ƙasashe nan da shekara mai zuwa.
Ƙwararru kan kiwon lafiya na tafka muhawara kan “ainahin amfanin” lecanemab.
An gano yadda take rage matsalar ne ta hanyar tantance girman matsalar maras lafiya. Matakai ne 18 da suka ƙunshi daidai zuwa mafi tsanani. Waɗanda suka samu maganin sun fi waɗanda ba su samu ba da kashi 0.45 cikin 100.
Farfesa Spires-Jones ya ce wannan “ƙaramin abu ne” game da cutar, amma “duk da cewa babu yawa, na amince da shi”.
Dr Susan Kohlhaas ta Alzheimer’s Research UK, ta ce cigaba ne marar yawa, amma mun samu ‘yar makama” kuma magungunan da za a samu nana gaba za su fi haka inganci.
Akwai kuma haɗari. Hoton ƙwaƙwalwa ya nuna akwai zubar jini (a kashi 17 cikin 100 na mutanen da aka gwada) da kuma kumburin ƙwaƙwalwa (kashi 13 cikin 100). Jimilla, kashi 7 cikin 100 na mutanen sai da suka daina shan maganin saboda matsalarsa.
Babban abin tambaya shi ne me zai faru bayan wata 18 na gwajin, kuma amsar har yanzu canke-canke kawai ake yi babu wamda ya sani amsar. Allah Ya sa mu dace, Amin.
Wasiƙa daga MUHAMMAD AUWAL MUSA (Ya Muha), 08062327373.